Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
EUROPEAN JOURNAL OF CANCER, vol.50, no.6, pp.1090-1099, 2014 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 50 Issue: 6
- Publication Date: 2014
- Doi Number: 10.1016/j.ejca.2014.01.006
- Journal Name: EUROPEAN JOURNAL OF CANCER
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.1090-1099
- Hacettepe University Affiliated: Yes
Abstract
Background: Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel. Subsequently, compassionate-use programmes (CUPs) and expanded-access programmes (EAPs) were established worldwide, allowing access to cabazitaxel before its commercial availability. Preliminary results of the European CUP/EAP, focusing on the elderly population (aged >= 70 years), are reported.